Intec Pharma (NASDAQ:NTEC) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, MarketWatch Earnings reports.
NTEC stock traded up $0.01 on Friday, hitting $5.89. 126,488 shares of the company were exchanged, compared to its average volume of 130,876. Intec Pharma has a twelve month low of $3.55 and a twelve month high of $7.50. The firm has a market capitalization of $193.02 million, a price-to-earnings ratio of -3.57 and a beta of 0.71.
A number of equities analysts have recently weighed in on the stock. HC Wainwright set a $16.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 16th. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. Finally, Roth Capital assumed coverage on shares of Intec Pharma in a research report on Friday, October 5th. They issued a “buy” rating and a $8.50 price objective for the company. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Intec Pharma currently has a consensus rating of “Buy” and a consensus target price of $11.40.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
See Also: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.